{"id":"W4296797608","doi":"10.1093/oncolo/oyac192","title":"Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Everolimus; Medicine; Clinical endpoint; Renal cell carcinoma; Internal medicine; Adverse effect; Oncology; Randomized controlled trial; Urology; Tolerability; Phases of clinical research; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002570669,0.002105874,0.004083948,0.0005389636,0.0005450267,0.001629436,0.00116008,0.00188095,0.00704782],"category_scores_gemma":[0.001823584,0.00101453,0.002039459,0.0005123392,0.001502623,0.0013831,0.0005346835,0.004182629,0.001357209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001109691,"about_ca_system_score_gemma":0.002276113,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008127019,"about_ca_topic_score_gemma":0.001931361,"domain_scores_codex":[0.9991404,0.0004533199,0.00005394863,0.0001479168,0.00005837846,0.0001460109],"domain_scores_gemma":[0.9985056,0.0003314007,0.0003013699,0.0001320775,0.0000794642,0.0006501065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9834984,0.007293691,0.0003821034,0.0001564425,0.000388652,0.00002577935,0.00002632267,0.000340018,0.001781831,0.00007059404,0.0003755679,0.005660575],"study_design_scores_gemma":[0.9232886,0.07496997,0.0005455185,0.00000890126,0.000167995,0.00002101341,0.00001163361,0.000314273,0.0002544016,0.00009813575,0.0003121227,0.000007493189],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845712,0.00269302,0.0007746008,0.0009771223,0.001065507,0.006676691,0.001158747,0.0001224421,0.001960687],"genre_scores_gemma":[0.982721,0.001579008,0.001501273,0.001587586,0.0007628985,0.006926181,0.001590744,0.00002679537,0.003304392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00704782,"threshold_uncertainty_score":0.02357733,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01675006100570516,"score_gpt":0.2691139331315795,"score_spread":0.2523638721258744,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}